Bioptix, Inc. (NASDAQ:BIOP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On January 6, 2017, Bioptix, Inc. (the “Company”) appointed
John O’Rourke and Mike Dai as directors of the Company
following the resignation of Gail S. Schoettler, Susan A. Evans
and David E. Welch from the Board of Directors of the Company.
Mr. O’Rourke and Mr. Dai constitute independent non-employee
directors as defined by NASDAQ Rule 5605(a)(2). Mr. O’Rourke
constitutes an audit committee financial expert within the
meaning of Item 407(d)(5(ii) of Regulation S-K promulgated
under the Securities Act of 1933, as amended. Mr. Beeghley, Mr.
O’Rourke and Mr. Dai were each appointed to the Nominating and
Governance Committee (Mr. Beeghley, Chairman), Audit Committee
(Mr. O’Rourke Chairman) and Compensation Committee (Mr. Dai
Chairman) and all other directors were removed from such
committees.
Mr. O’Rourke is an analyst and investor who currently serves
as Managing Member of ATG Capital LLC, an investment fund
focused on small and mid-cap growth companies possessing
distinct competitive advantages and superior management teams.
Mr. O’Rourke currently serves on the Board of Directors of
Customer Acquisition Network Inc., a leading global performance
based marketing company that reaches more than two billion
users per month. Mr. O’Rourke formerly served on the Board of
Directors of Rant, Inc., an innovator in U.S. digital media,
prior to its sale to a Nasdaq listed company. He was formerly
CFO of Fidelity Property Group, a real estate development
company with a focus in California. He received his Bachelor of
Science in Accounting with Honors from the University of
Maryland and a Master of Science in Finance from George
Washington University.
Mr. Dai has been an associate with ALOE Finance Inc., a
financial consulting and transaction advisory firm since 2012.
Prior to his involvement with ALOE Finance, Mr. Dai held
various roles at Grant Thornton LLP, an audit, tax and advisory
firm between 2007 and 2012. Mr. Dai also serves as chief
financial officer and director of Santa Maria Petroleum Inc.
(TSXV:SMQ.H), a position he has held since 2014.
Each of the resigning directors affirmed that the resignation
was not related to any disagreement or concerns related to the
financial status or financial statements of the Company.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibits
99.1 |
Letter of Resignation
|
About Bioptix, Inc. (NASDAQ:BIOP)
Bioptix, Inc., formerly Venaxis, Inc., provides Enhanced Surface Plasmon Resonance (SPR) platform for the detection of molecular interactions. The Company’s line of Enhanced SPR instruments are designed to increase the flexibility and reliability of SPR. Its SPR biosensors shed light on important binding parameters that are crucial for determining whether a biologic or small molecule drug will be efficacious in humans and at what dose a drug should be administered. Its technology is an ultra-sensitive detection platform. The design of its SPR spectrometers allows discrete areas within the sample cell to be interrogated simultaneously by use of photo-diode arrays aligned to the reflected beam from the sample cell. Its biosensors provide information on kinetic processes (association and dissociation), binding affinities, analyte concentrations and real-time molecule detection. The Company offers 404pi Enhanced SPR System, which enables real-time detection of biomolecular interactions. Bioptix, Inc. (NASDAQ:BIOP) Recent Trading Information
Bioptix, Inc. (NASDAQ:BIOP) closed its last trading session down -0.04 at 4.10 with 1,607 shares trading hands.
